# Róbert Gábor Kiss

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-gabor-kiss/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,048 |
| Field | Antiplatelet Therapy and Cardiovascular Diseases |
| h-index | 45 |
| i10-index | 100 |
| Last Known Institution | Semmelweis University |
| OpenAlex ID | https://openalex.org/A5015803547 |
| ORCID iD | https://orcid.org/0000-0003-0514-7530 |
| Works | 216 |

## Researcher papers

- [2015 ESC Guidelines for the diagnosis and management of pericardial diseases](https://scholariq.org/papers/2015-esc-guidelines-for-the-diagnosis-and-management-of-pericardial-diseases/)
- [Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction](https://scholariq.org/papers/long-term-use-of-ticagrelor-in-patients-with-prior-myocardial-infarction/)
- [ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)](https://scholariq.org/papers/esc-guidelines-on-the-management-of-cardiovascular-diseases-during-pregnancy-the/)
- [2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes](https://scholariq.org/papers/2023-esc-guidelines-for-the-management-of-cardiovascular-disease-in-patients/)
- [The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial](https://scholariq.org/papers/the-sglt2-inhibitor-empagliflozin-in-patients-hospitalized-for-acute-heart/)
- [Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus](https://scholariq.org/papers/effect-of-dapagliflozin-on-atrial-fibrillation-in-patients-with-type-2-diabetes/)
- [2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias](https://scholariq.org/papers/2025-focused-update-of-the-2019-esc-eas-guidelines-for-the-management-of/)
- [Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial](https://scholariq.org/papers/effects-of-alirocumab-on-cardiovascular-and-metabolic-outcomes-after-acute/)

## Researcher topics

- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)

## Researcher university

- [Semmelweis University](https://scholariq.org/institutions/semmelweis-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.